Pharmafile Logo
Pharmafocus logo
Advanced Search

Asthma & COPD

Showing 6 posts of 6 posts found.

Andera Partners leads financing for asthma treatment company Spiro Medical

January 5, 2026
Sales and Marketing Andera Partners, Asthma & COPD, Spiro Medical

Andera Partners, a private equity firm, has announced its leadership of a $67m series A financing round in Spiro Medical, …

News

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025
Regulatory Affairs, Research and Development Asthma & COPD, GSK

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) …

News
mobile apps

electronRx to launch pDx app for remote monitoring of chronic respiratory disease

September 18, 2025
Research and Development Asthma & COPD, Devices, devices, electronRx, pDx, respiratory diseases (CRDs)

Digital medicine company electronRx, based in Cambridge, UK, has announced the upcoming launch of pDx, a mobile app designed to …

News

GSK shares positive results from phase 3 asthma trials

May 21, 2024
Research and Development Asthma & COPD, GSK, asthma, clinical trial

GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which evaluated the safety and efficacy …

News

GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trials 

November 21, 2023
Medical Communications Asthma & COPD, GSK, Ventolin, asthma, carbon-neutral

GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its …

News
inhaler-2520472_960_720

Lupin Healthcare launches Beclu carbon neutral inhalers for asthma treatment

June 22, 2023
Research and Development Asthma & COPD, Beclu, Lupin Healthcare, asthma, carbon neutral, inhaler

UK-based subsidiary of Lupin Limited, Lupin Healthcare, has announced the UK launch of its carbon neutral pressurised metered dose inhalers …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026